Nyxoah (NYXH) Competitors

OrthoPediatrics has higher revenue and earnings than Nyxoah. OrthoPediatrics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

In the previous week, OrthoPediatrics had 11 more articles in the media than Nyxoah. MarketBeat recorded 13 mentions for OrthoPediatrics and 2 mentions for Nyxoah. OrthoPediatrics' average media sentiment score of 0.49 beat Nyxoah's score of 0.00 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Nyxoah currently has a consensus price target of $9.33, indicating a potential upside of 214.25%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 43.54%. Given Nyxoah's higher possible upside, analysts plainly believe Nyxoah is more favorable than OrthoPediatrics.

Nyxoah has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

69.1% of OrthoPediatrics shares are held by institutional investors. 32.7% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

OrthoPediatrics has a net margin of -16.31% compared to Nyxoah's net margin of -884.69%. OrthoPediatrics' return on equity of -6.95% beat Nyxoah's return on equity.

In the previous week, Delcath Systems and Delcath Systems both had 2 articles in the media. Delcath Systems' average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score.

61.1% of Delcath Systems shares are held by institutional investors. 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Delcath Systems has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Delcath Systems presently has a consensus price target of $22.50, suggesting a potential upside of 95.14%. Nyxoah has a consensus price target of $9.33, suggesting a potential upside of 214.25%. Given Nyxoah's higher possible upside, analysts clearly believe Nyxoah is more favorable than Delcath Systems.

Delcath Systems has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Delcath Systems has a net margin of 3.17% compared to Nyxoah's net margin of -884.69%. Delcath Systems' return on equity of 2.63% beat Nyxoah's return on equity.

CapsoVision has higher revenue and earnings than Nyxoah. CapsoVision is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

CapsoVision presently has a consensus price target of $8.50, suggesting a potential upside of 19.72%. Nyxoah has a consensus price target of $9.33, suggesting a potential upside of 214.25%. Given Nyxoah's higher possible upside, analysts clearly believe Nyxoah is more favorable than CapsoVision.

CapsoVision has a net margin of 0.00% compared to Nyxoah's net margin of -884.69%. CapsoVision's return on equity of 0.00% beat Nyxoah's return on equity.

In the previous week, CapsoVision and CapsoVision both had 2 articles in the media. CapsoVision's average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score.

ClearPoint Neuro has higher revenue and earnings than Nyxoah. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Nyxoah has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Nyxoah currently has a consensus price target of $9.33, suggesting a potential upside of 214.25%. ClearPoint Neuro has a consensus price target of $14.50, suggesting a potential upside of 30.51%. Given Nyxoah's stronger consensus rating and higher probable upside, analysts clearly believe Nyxoah is more favorable than ClearPoint Neuro.

30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ClearPoint Neuro has a net margin of -69.08% compared to Nyxoah's net margin of -884.69%. ClearPoint Neuro's return on equity of -122.17% beat Nyxoah's return on equity.

In the previous week, Nyxoah had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 2 mentions for Nyxoah and 1 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.36 beat Nyxoah's score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the news media.